Prime Medicine, Valuation
| PRME Etf | USD 2.54 0.11 4.15% |
Based on Macroaxis valuation methodology, the etf appears to be undervalued. Prime Medicine, Common holds a recent Real Value of $4.03 per share. The prevailing price of the etf is $2.54. Our model determines the value of Prime Medicine, Common from analyzing the etf fundamentals such as Shares Owned By Insiders of 23.90 %, current valuation of 246.09 M, and Return On Equity of -1.14 as well as examining its technical indicators and probability of bankruptcy.
Price Book 2.0072 | Enterprise Value 246.1 M | Enterprise Value Ebitda (3.10) | Price Sales 434.4708 | Enterprise Value Revenue 307.6093 |
Undervalued
Today
Please note that Prime Medicine,'s price fluctuation is risky at this time. Calculation of the real value of Prime Medicine, Common is based on 3 months time horizon. Increasing Prime Medicine,'s time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Prime etf is determined by what a typical buyer is willing to pay for full or partial control of Prime Medicine, Common. Since Prime Medicine, is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Prime Etf. However, Prime Medicine,'s intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.54 | Real 4.03 | Target 13.7 | Hype 2.65 | Naive 3.09 |
The real value of Prime Etf, also known as its intrinsic value, is the underlying worth of Prime Medicine, Common ETF, which is reflected in its stock price. It is based on Prime Medicine,'s financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Prime Medicine,'s stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Prime Medicine, Common helps investors to forecast how Prime etf's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Prime Medicine, more accurately as focusing exclusively on Prime Medicine,'s fundamentals will not take into account other important factors: Prime Medicine, Total Value Analysis
Prime Medicine, Common is at this time expected to have valuation of 246.09 M with market capitalization of 347.58 M, debt of 13.63 M, and cash on hands of 146.66 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Prime Medicine, fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
246.09 M | 347.58 M | 13.63 M | 146.66 M |
Prime Medicine, Asset Utilization
One of the ways to look at asset utilization of Prime is to check how much profit was generated for every dollar of assets it reports. Prime Medicine, holds a negative application of assets of -0.47 pct., losing $0.004651 for each dollar of assets held by the etf. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of Prime Medicine, Common shows how discouraging it operates for each dollar spent on its assets.Prime Medicine, Ownership Allocation
Prime Medicine, owns a total of 131.16 Million outstanding shares. Over half of Prime Medicine,'s outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company maintains, if the real value of the etf is less than the current market value, you may not be able to make money on it.Prime Medicine, Profitability Analysis
Net Loss for the year was (198.13 M) with loss before overhead, payroll, taxes, and interest of (161.84 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Prime Medicine,'s worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Prime Medicine, and how it compares across the competition.
About Prime Medicine, Valuation
The etf valuation mechanism determines Prime Medicine,'s current worth on a weekly basis. Our valuation model uses a comparative analysis of Prime Medicine,. We calculate exposure to Prime Medicine,'s market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Prime Medicine,'s related companies.Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. Prime Medicine is listed under Biotechnology in the United States and is traded on NASDAQ Exchange exchange.
Prime Medicine, Growth Indicators
Investing in growth stocks can be very risky. If the company such as Prime Medicine, does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 91 M |
Other Information on Investing in Prime Etf
Prime Medicine, financial ratios help investors to determine whether Prime Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Prime with respect to the benefits of owning Prime Medicine, security.